New Delhi, February 27 Zenex Animal Health India, an animal health company, has acquired a majority stake in VievePharm, a specialist in natural animal nutrition based in the Netherlands, for an undisclosed sum, the company said on Friday.
The deal gives Zenex a manufacturing and sales base in Western Europe and expands its portfolio of natural and herbal animal health products, as regulatory pressure mounts on the use of veterinary antibiotics across the European Union.
Headquartered in Enter, Netherlands, VievePharm specializes in phytogenic formulations for the livestock, equine, and pet care markets.
The acquisition builds on Zenex's 2023 purchase of Ayurvet, which established its Ayurvedic animal health portfolio.
VievePharm's expertise in bolus technology used to deliver minerals, vitamins, and support for udder health will be integrated into Zenex's broader product offering globally.
The deal comes as the EU's Farm to Fork Strategy targets a 50% reduction in veterinary antibiotic sales by 2030 compared to 2018 levels, a trend Zenex said would benefit its combined naturals portfolio.
"By combining VievePharm's advanced bolus technology and European market access with our R&D depth and global distribution, we are positioned to offer holistic, science-backed solutions," said Arun Atrey, Managing Director and CEO of Zenex, in a statement.
Zenex currently has operations across Asia, Africa, and parts of the CIS region. The acquisition is intended to accelerate its entry into Western European markets using VievePharm's established distribution network.
